Cover Image

225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical sit...

Full description

Saved in:
Bibliographic Details
Main Authors: Kratochwil, Clemens (Author) , Giesel, Frederik L. (Author) , Haberkorn, Uwe (Author)
Format: Article (Journal)
Language:English
Published: July 7, 2016
In: Journal of nuclear medicine
Year: 2016, Volume: 57, Issue: 12, Pages: 1941-1944
ISSN:2159-662X
DOI:10.2967/jnumed.116.178673
Online Access:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.2967/jnumed.116.178673
Verlag, kostenfrei, Volltext: http://jnm.snmjournals.org/content/57/12/1941
Get full text
Author Notes:Clemens Kratochwil, Frank Bruchertseifer, Frederik L. Giesel, Mirjam Weis, Frederik A. Verburg, Felix Mottaghy, Klaus Kopka, Christos Apostolidis, Uwe Haberkorn, and Alfred Morgenstern
Description
Summary:Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy. Methods: 68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT. Results: Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect. Conclusion: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Item Description:Gesehen am 07.11.2017
Physical Description:Online Resource
ISSN:2159-662X
DOI:10.2967/jnumed.116.178673

Similar Items